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Peritoneal membrane failure may develop during long-
term peritoneal dialysis (PD). It is characterized by the
occurrence of ultrafiltration failure [1] and by morpho-
logic alterations in the peritoneal tissues. These alterna-
tions consist of an increased thickness of the collagenous
submesothelial compact zone of the parietal peritoneum,
sometimes accompanied by loss of surface mesothelium
[2, 3]. Vascular abnormalities also have been described,
including an increase in the number of vessels [3, 4];
subendothelial hyalinosis, especially of the venules and
small veins, but also of arterioles [3, 5], and extensive
diabetiform lamellation of the capillary and mesothelial
basement membranes [6–8]. Advanced glycosylation end
products (AGEs) are found in peritoneal tissues, espe-
cially around the vascular wall [9, 10]. Multiple peritonitis
episodes might accelerate the development of these func-
tional and anatomic alterations, but are clearly not the
only source [11]. The induction of diabetiform peritoneal
alterations in a peritonitis-free, long-term peritoneal ex-
posure model in the rat [12], and the relationship with
the cumulative peritoneal glucose exposure in humans
[13, 14], point to an important contribution by the current
bioincompatible glucose-based dialysis solutions, and the
need for new solutions that by their more favorable ef-
fects on the peritoneum and the patient as a whole can
improve both PD technique and patient survival.
BIOCOMPATIBILITY ASPECTS OF
PERITONEAL DIALYSIS SOLUTIONS
Biocompatibility of a PD solution can be defined as the
ability of the solution to cause as little change as possible
to the structure and function of the peritoneal membrane,
thus allowing PD to be successful as a long-term renal
replacement modality. Components of the solution can
affect cellular elements of the peritoneal membrane, re-
sulting in alterations of cytokine, chemokine, and growth
factor production. They also can cause upregulation of
proinflammatory and profibrotic processes, impairment
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of peritoneal defense, and induction of carbonyl and ox-
idative stress. From a clinical viewpoint, these effects may
be seen acutely in the form of pain and discomfort at the
time of solution infusion, or more chronically, as peritoni-
tis due to impaired peritoneal host defense, loss of ultra-
filtration, and development of encapsulating peritoneal
sclerosis as a result of membrane changes. Biocompati-
bility of glucose-based dialysis solutions is compromised
because of 5 main factors: low pH, lactate buffer, high
glucose content, high osmolality, and the presence of glu-
cose degradation products (GDPs). These factors will be
discussed below and are summarized in Table 1.
Low pH and lactate
A PD solution with pH 5.5 may cause pain on infu-
sion in some patients. The combination of low pH and
lactate has been shown in in vitro studies to be extremely
toxic to mesothelial and other cells because it causes a de-
crease in intracellular pH, which is partly irreversible [15].
This effect is probably less important in patients, because
the instilled solution is diluted immediately with the in-
traperitoneal residual dialysate volume, leading to a steep
rise in pH [16]. Toxicity of lactate has been suggested in in
vitro studies that showed that pyruvate induced less cyto-
toxicity to peritoneal macrophages and mesothelial cells
than lactate [17]. This finding could partly be attributed to
the lower pKa of pyruvate, making it a weaker buffer, but
also to its ability to scavenge oxygen radicals [18]. Pyru-
vate also causes less stimulation of intracellular degrada-
tion of glucose in the polyol pathway [19]. A recent study
reported that the addition of lactate to cultured human
peritoneal mesothelial cells, either alone or in combina-
tion with glucose, enhanced secretion of transforming
growth factor beta (TGF-b1), and monocyte chemoat-
tractant protein-1 (MCP-1). The glucose-induced se-
cretion of TGF-b1 and MCP-1 was antagonized when
lactate was replaced by pyruvate [20]. These results make
it likely that lactate at very high concentrations enhances
glucose-mediated peritoneal toxicity.
Glucose
PD solutions contain extremely high concentrations of
glucose. In fresh solutions, the concentration varies from
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Table 1. Factors contributing to the bioincompatibility of conventional, heat-sterilized, glucose/lactate-based solutions
In vitro In vivo
Low pH and lactate Intracellular pH ↓ Infusion pain
Lactate Some cytotoxicity May contribute to glucose toxicity
Glucose Direct mesothelial toxicity Direct mesothelial toxicity
Cytotoxicity by stimulation of the polyol pathway Neoangiogenesis
Formation of AGEs
GDPs Cytotoxicity mainly in high concentrations Formation of AGEs
VEGF production
Hyperosmolality Some cytotoxicity May be relatively harmless, but insufficient data
GDPs, glucose degradation products; AGEs, advanced glycolysation end products.
75 mmol/L (1.36%) to 215 mmol/L (3.86%), which is 15
to 40 times higher than the normal plasma level. At the
end of a dwell, the dialysate glucose concentration range
is between 20 and 70 mmol/L. Therefore, the tissues of
the peritoneal membrane are continuously exposed to
glucose concentrations that clearly are in the diabetic
range. Such high concentrations of glucose are toxic to
the mesothelium, both in in vitro and in animal studies
[21, 22]. Furthermore, glucose activates the polyol path-
way and the secretion of TGF-b1, MCP-1, and fibronectin
by cultured mesothelial cells [20, 23]. These in vitro data
suggest that glucose is involved in the development of
peritoneal fibrosis.
Glucose also is likely to be involved in the development
of peritoneal neoangiogenesis, as evidenced by the dia-
betiform alterations of the peritoneal microvessels that
are present in patients [6–8] and can be induced in animal
models [12]. The finding of local peritoneal production of
vascular endothelial growth factor (VEGF) [24], the ef-
fluent concentration of which increases with the duration
of PD [25], clearly underlines the similarity with diabetic
retinopathy. The clinical importance of this diabetiform
neoangiogenesis is that it leads to enlargement of the peri-
toneal vascular surface area, which causes high rates of
diffusion of low molecular weight osmotic agents from
the peritoneal cavity. The result is a rapid disappearance
of the osmotic gradient and consequently impairment of
ultrafiltration.
A third mechanism by which glucose can damage the
peritoneal tissue is by inducing nonenzymatic glycosy-
lation of tissue proteins, which leads to the formation
of Amadori adducts and AGEs. Peritoneal deposition
of AGEs, particularly in the vascular wall, has been
demonstrated in immunohistochemical studies [9, 10],
and their presence has been linked with ultrafiltration
failure [26]. The contribution of glucose is superimposed
on the presence of uremia, which itself is associated with
increased plasma levels of AGEs, such as pentosidine and
carboxymethyllysine [27–29]. This so-called “carbonyl-
stress” is probably caused by the low molecular weight
reactive carbonyl compounds (RCOs), which accumulate
in uremia [30, 31]. Early and advanced glycosylation end
products are likely to be involved in the pathogenesis of
vascular intimal hyperplasia [32], and in monocyte acti-
vation in uremia [33]. They also enhance endothelial ni-
tric oxide synthase activity [34]. It is therefore likely that
AGEs are involved in the peritoneal membrane alter-
ations of long-term PD, especially as effluent concentra-
tions of pentosidine increase with the duration of PD [35].
In accordance, a recent study in the long-term peritoneal
exposure model in the rat showed that intraperitoneal
administration of aminoguanidine, an inhibitor of AGE
formation, partly prevented the development of the vas-
cular and fibrotic peritoneal changes induced by exposure
to high glucose conventional dialysis solutions [abstract;
Zweers MM, Perit Dial Int 22(Suppl):S18, 2002].
Glucose degradation products
GDPs are formed during heat sterilization of dial-
ysis solutions and, to a lesser extent, during storage.
The cytotoxicity induced by heat sterilization was first
described by Wieslander et al [36]. Glucose degra-
dation products consist of aldehydes and dicarbonyl
compounds. Aldehydes include formaldehyde, 5-OH
methylfuraldehyde, acetaldehyde, and 2-furaldehyde. Di-
carbonyl compounds include glyoxal, methylglyoxal,
and 3-deoxyglucosone. Recently, 3,4-dideoxyglucosone-
3-ene (3,4-DGE) has been detected in PD solutions [37]
and was cytotoxic in concentrations present in conven-
tional solutions. Glucose degradation products may affect
the peritoneal membrane by 3 mechanisms. First, they are
toxic not only to mouse fibroblasts, but also to cultured
human mesothelial cells [38]. Second, methylglyoxal en-
hances the production of VEGF by peritoneal cells [39].
Finally, GDPs are RCOs that trigger the formation of
AGEs at a much faster speed than glucose. The relative
contribution of glucose and GDPs to peritoneal AGE for-
mation in vivo is unknown. GDPs are much more active
carbonyl compounds than glucose, but their concentra-
tion in conventional dialysis solutions is much lower; for
example, 22 lmol/L for 3,4-DGE versus 215 mmol/L for
glucose. The RCOs in uremic plasma and the GDPs in
dialysis solutions cross the peritoneal membrane in op-
posite directions. As a consequence, GDP levels decrease
during a dwell [38, 39], but RCOs in the dialysate increase
[40]. When a dialysis solution with a low GDP content was
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Table 2. Improvements in biocompatibility and dialysis performance of the new PD solutions
In vitro In vivo
Icodextrin Cytotoxicity ↓ Long dwell UF ↑
Mesothelial proliferation ↑ UF failure
Phagocytosis↑ Peritonitis
Metabolic advantages (glucose, lipids)
Better control of fluid status
Improvement in symptoms and quality of life
1.1% amino acid solution Cytotoxicity ↓ Delivers 25% of target protein intake without phosphorus
Phagocytosis ↑ Protein synthesis ↑
Improves some parameters of nutritional status
Bicarbonate/lactate-buffered solution Cytotoxicity ↓ Animals: mesothelial integrity ↑
Cell functions ↑ Number of peritoneal vessels ↓
Omental fibrosis ↓
Humans: inflow pain ↓
increase UF ↑,
? peritonitis incidence ↓, dialysate CA 125 ↑,
dialysate hyaluronan ↓
Abbreviations are: PD, peritoneal dialysis; UF, ultrafiltration; CA 125, cancer antigen 125.
used chronically, the level of AGEs in the circulation was
lower [41]. The formation of GDPs can be markedly re-
duced by sterilizing a high concentration of glucose (e.g.,
50%) at a very low pH (e.g., pH 3). This requires the
use of double-chamber dialysis bags, which separates the
glucose from the solution buffer.
Hyperosmolality
The possible effects of hyperosmolality on the peri-
toneal membrane have been studied mainly in vitro by
comparing the effects of glucose and mannitol. In gen-
eral, replacement of glucose with mannitol mitigated
but did not totally reverse the effects of glucose, sug-
gesting some contribution of hyperosmolality per se.
This observation has been described for mesothelial cell
growth [21], the intercellular mesothelial cell junctions
[42], and the production of various substances by cul-
tured peritoneal mesothelial cells, including synthesis
of prostaglandin E2 [43], tissue-type plasminogen ac-
tivator [44], TGF-b [20, 45, 46], MCP-1 [20], and fi-
bronectin [23, 45]. Hyperosmolality also suppresses the
synthesis of metalloproteinase-9 by human peritoneal
mesothelial cells [47]. Glucose and osmolality had in-
dependent effects on the release of tumor necrosis
factor-a (TNF-a) and interleukin-6 (IL-6) by monocytes.
Hyperosmolality decreased phagocytosis and the secre-
tion of leukotrien-4 by polymorphonuclear cells inde-
pendently of glucose [48]. The results of these in vitro
studies for the in vivo situation are not well established.
One in vivo study in rodents reported that the effect
of high glucose exposure on the peritoneal mesothelial
monolayer was independent of its osmolality [49], but
this result will have to be confirmed in other studies.
It can be concluded that standard glucose-based PD
solutions have long-term detrimental effects on the peri-
toneum due to the presence of high levels of lactate,
glucose, and GDPs, and low pH, which may result in
diminished defense mechanisms and ultrafiltration fail-
ure. Furthermore, absorption of glucose from these solu-
tions contributes to hyperglycemia, obesity, and insulin
resistance, which are risk factors for cardiovascular dis-
ease. A number of new solutions containing different
buffers and osmotic agents have been developed with
the goal of improving both patient and technique sur-
vival. These solutions have been used individually or in
combination as replacements for glucose in one or more
daily exchanges.
NEW DIALYSIS SOLUTIONS
The new dialysis solutions that have been developed
to improve biocompatibility and clinical outcome are dis-
cussed below and summarized in Table 2.
Icodextrin
Icodextrin is a mixture of high molecular weight glu-
cose polymer fractions of hydrolyzed cornstarch with a
mean molecular weight of 16 kD. The commercial prod-
uct contains 7.5% icodextrin in a lactate buffer (Ex-
traneal, Baxter Healthcare Corporation, McGaw Park,
IL, USA). The solution has an osmolality of 284 mOsm/kg
H2O and exerts a colloid osmotic pressure gradient,
in contrast to the crystalloid osmotic pressure induced
by low molecular weight osmotic agents [50]. The pH
of the solution is 5.8 and it contains a lower amount
of GDPs than a 1.36% glucose solution. The first in
vitro study of the biocompatibility of 7.5% icodextrin
showed no improvement compared to glucose-based so-
lutions [51]. However, at neutral pH the secretion of IL-6
by monocytes was superior to that after exposure to
a 1.5% glucose-based solution [52]. More recently, im-
proved phagocytosis by peripheral polymorphonuclear
cells and monocytes has been described after stimula-
tion with icodextrin compared to standard solutions [53].
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Ex vivo studies have shown improved phagocytosis of
peritoneal macrophages when isolated from icodextrin
effluent compared to those from glucose effluent [54].
Similarly, the proliferation capacity of mesothelial cells
in icodextrin effluent was better [55].
Two large prospective, randomized, controlled trials
with durations of 6 months to 1 year have been performed
using 7.5% icodextrin for the long dwell of continuous
ambulatory peritoneal dialysis (CAPD), one in the UK
[56] and one in the United States [57]. Icodextrin pro-
duced greater ultrafiltration than 1.36% glucose (1.5%
dextrose) and 2.27% glucose (2.5% dextrose). Ultrafil-
tration was similar to that achieved with 3.86% glucose
(4.25% dextrose) during 8-hour exchanges, but tended
to be higher during 12-hour dwells. These observations
are explained by the high molecular weight of icodex-
trin, which limits diffusion across the peritoneum. Con-
sequently, the osmotic gradient remains present for a
much longer time than when low molecular weight os-
motic agents are used. Similar results have been reported
when icodextrin was used for the long dwell in patients on
automated peritoneal dialysis (APD) [58, 59]. The higher
ultrafiltration rates on icodextrin resulted in higher peri-
toneal creatinine clearances [57, 60].
Icodextrin as salvage therapy in chronic PD patients
with ultrafiltration failure
The presence of a high peritoneal transport status, re-
flecting a large peritoneal vascular surface area, leads to
a reduction in ultrafiltration with glucose-based dialysis
solutions due to a high diffusion rate of glucose. However,
in the presence of a stable osmotic gradient, a large vas-
cular surface area will be associated with a high transport
rate of fluid. This has indeed been found for icodextrin.
Patients with high solute transport rates had a signifi-
cantly higher ultrafiltration volume on icodextrin com-
pared with during use of glucose [61]. This finding has
led to the use of icodextrin as salvage therapy in PD pa-
tients with ultrafiltration failure, especially in those who
develop increasing diffusive transport of low molecular
weight solutes after 3 to 5 years on PD. Some retrospec-
tive studies reported that icodextrin enabled patients who
would otherwise have been transferred to hemodialysis
[62, 63] to remain on PD, an observation that was re-
cently confirmed in a prospective, open-label study of 17
patients [64]. In this study, icodextrin was substituted for
4.25% dextrose for the long-dwell exchange in patients
who were on the verge of being transferred to hemodial-
ysis because of symptomatic fluid retention that was
unresponsive to fluid restriction, loop diuretic therapy,
hypertonic glucose exchanges, and dwell-time optimiza-
tion. Icodextrin increased daily peritoneal ultrafiltration
by 599 mL and reduced mean arterial pressure by 10 mm
Hg. There were no changes in weight, plasma albumin
concentration, hemoglobin level, or dialysate/plasma cre-
atinine ratio. Overall, PD technique survival was pro-
longed by a mean of 11.6 months.
Icodextrin in peritonitis-induced ultrafiltration failure
Loss of ultrafiltration capacity is a common and con-
sistent finding in episodes of peritonitis. Several studies
have reported the changes in membrane transport char-
acteristics that occur during and after an episode of peri-
tonitis using standard peritoneal permeability analyses
[65–67]. The mass transfer area coefficients (MTACs)
of low molecular weight solutes are increased in peri-
tonitis: urea, 26%, creatinine, 45%, and urate, 45%.
Transport of glucose, carbon dioxide, and peritoneal pro-
teins is similarly increased. The loss of ultrafiltration
is due predominantly to the rapid dissipation of the
glucose-dependent osmotic gradient. Also, unlike other
inflammatory conditions, peritonitis is not associated with
enhanced lymphatic absorption as demonstrated by
Carlsson and Rippe [66, 68]. This acute, transient state
of very high transport and relatively unaffected lym-
phatic transport induced by the inflammatory process al-
lows icodextrin to achieve ultrafiltration by virtue of the
fact that icodextrin exerts colloid osmotic pressure and is
removed from the peritoneum via convective pathways
through the lymphatics.
Several studies have now demonstrated that ultrafiltra-
tion declines during peritonitis with the use of glucose-
based solutions, while it remains stable or increases with
icodextrin-based solutions [69–71]. Icodextrin is there-
fore crucial for maintaining ultrafiltration and prevent-
ing fluid retention and weight gain during episodes of
peritonitis.
Icodextrin as a long-term biocompatible dialysis solution
Icodextrin-based solutions are clearly more biocom-
patible than their glucose-based counterparts and could
be used as an alternative to glucose from the outset of PD
therapy. In addition to increasing ultrafiltration volume,
they enhance the convective transport of low molecular
weight proteins such as b2-microglobulin and leptin [60,
72, 73].
Although intraperitoneal and oral administration of
glucose solutions results in an elevation of plasma glu-
cose in the initial few hours, the hyperglycemia and hy-
perinsulinemia induced by intraperitoneal instillation are
more persistent and add to the metabolic cost of achieving
higher ultrafiltration with a glucose-based solution [74].
Diabetic patients on icodextrin experienced improve-
ment in glycemic control as evidenced by a decrease in
HbA1c from 8.9 ± 0.7% to 7.9 ± 0.7%. Seven of the
12 patients in that study required a reduction in insulin
dose.
The impact of 7.5% icodextrin on blood pressure (BP)
compared to 2.27% glucose was evaluated in 14 patients
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during the long daytime dwell of APD [75]. Blood pres-
sure determinations were made during treatment with
2.27% glucose and then repeated 1 month after switch-
ing to icodextrin. Icodextrin was associated with reduc-
tions in both systolic (SBP) and diastolic blood pressure
(DBP). Significant reductions occurred in 6 patients de-
spite a reduction in antihypertensive medication. Systolic
blood pressure fell from 143 to 123 mm Hg, and DBP fell
from 83 to 77 mm Hg. Changes in SBP significantly corre-
lated with changes in body weight, estimates of total body
water, extracellular water, and extracellular/intracellular
water (ECW/ICW) ratio. Changes in DBP significantly
correlated with changes in ECW and ECW/ICW ratio.
These findings demonstrated that the use of icodextrin
for the daytime dwell in APD improves fluid balance and
blood pressure control relative to conventional 2.27%
glucose.
A secondary analysis of fasting lipids was con-
ducted from a randomized open-label study comparing
overnight exchanges with 7.5% icodextrin and standard
glucose [abstract; Gokal R, J Am Soc Nephrol 9:283A,
1998]. A significant decline in total cholesterol (TC) and
low density lipoprotein (LDL) cholesterol (LDLc) was
observed after 6 months of treatment with icodextrin.
This effect was particularly evident for patients with base-
line hyperlipidemia. Baseline LDLc values for icodextrin
and glucose were 6.2 and 5.6 mmol/L, respectively. Fol-
lowing 6 months of treatment, hyperlipidemic patients
on icodextrin experienced a 16% reduction in LDLc on
average, which was significantly different from changes
noted among patients on glucose. Absolute LDLc values
after treatment were 5.2 mmol/L for icodextrin and 5.5
mmol/L for glucose. No significant changes in very low
density lipoprotein (VLDL) or high density lipoprotein
(HDL) cholesterol, plasma triglycerides, or Lp(a) were
observed.
Fluid status in PD patients is related to peritoneal
transport characteristics and residual renal function.
Compared to patients with residual glomerular filtration
rate (rGFR) >2 mL/min, ECW was significantly higher
in negligible GFR patients, despite a higher peritoneal ul-
trafiltration volume and a glucose prescription. This lon-
gitudinal study raised doubts whether an adequate fluid
state could be maintained using standard glucose solu-
tions in anuric patients without additional sodium and
fluid restriction [76]. In a randomized open-label study,
the same group also demonstrated that use of icodextrin
for the long dwell resulted in a significant reduction in
ECW and left ventricular mass over 4 months, compared
to a control group using standard glucose solutions. This
effect of icodextrin was related to the initial fluid state of
the patient, but not to peritoneal membrane characteris-
tics [77].
The impact of 7.5% icodextrin on quality of life (QOL)
was evaluated in a 52-week randomized, double-blind
active-controlled study using the Kidney Disease Quality
of Life (KDQOL) instrument [57]. A total of 66 patients
completed both the baseline and week 52 KDQOL ques-
tionnaires. Overall, QOL declined for patients in both
groups. However, significantly more patients treated with
icodextrin (30%) reported they felt better than 1 year ago
compared with patients treated with glucose (4%).
In the MIDAS Study (Multicenter Investigation of
Icodextrin in Ambulatory Peritoneal Dialysis), 7.5%
icodextrin was associated with a significantly greater re-
duction in overall CAPD-related symptom score at the
end of the 6-month study period compared with 1.5%
glucose [56]. Symptomatic improvement was particularly
evident for abdominal fullness, tiredness, shortness of
breath, and effective maintenance of dry weight.
The European Automated Peritoneal Dialysis Out-
comes Study (EAPOS) was a 2-year, multicenter eval-
uation of the feasibility and clinical outcomes of APD
in anuric patients [abstract; Davies SJ, Perit Dial Int
23(Suppl 1):S17, 2003). The aim of the study was to de-
termine the impact on technique and patient survival of
achieving the predetermined targets of a total creatinine
clearance of 60 L/wk/1.73 m2 and an ultrafiltration rate
of 750 mL/24 hr. At baseline, 45% of patients were us-
ing icodextrin to achieve adequate volume control. The
entire cohort experienced a significant increase in D/P
creatinine and a significant decrease in ultrafiltration ca-
pacity during the study. However, changes in these as-
pects of membrane function were significantly worse in
patients using either 2.27% or 3.86% glucose solutions
for the long dwell at baseline (P = 0.01), and significantly
less severe in patients using icodextrin (no change in ul-
trafiltration with icodextrin compared with marked re-
duction in ultrafiltration in nonusers). These differences
are particularly notable because at baseline, patients us-
ing icodextrin had significantly worse membrane func-
tion than those not using icodextrin (D/P creatinine 0.77
vs. 0.73, P < 0.024; ultrafiltration 274 vs. 374 mL, P <
0.016).
Despite its high level of biocompatibility and use in
a multitude of clinical situations, icodextrin poses some
problems of its own. A significant discrepancy has been
reported between glucose measurements using glucose
dehydrogenase-based methods and measurements ob-
tained in the laboratory using a reference method (hex-
okinase) [79, 80]. These methods overestimate plasma
glucose levels due to the presence of oligosaccharides
(mainly maltose) in the circulation and are therefore un-
suitable for use in patients on icodextrin. Dialysis with
icodextrin also interferes with the measurement of serum
amylase activity resulting in a reduction of serum amylase
levels. Serum amylase activity may be reduced by 90% as
a result of competitive interaction of icodextrin as a sub-
strate in the amylase assay [81]. However, because, unlike
amylase, icodextrin does not affect lipase activity, lipase
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measurement should be used for the diagnosis of sus-
pected pancreatitis in dialysis patients on icodextrin.
1.1% AMINO ACID SOLUTION
A 1.1% amino acid, lactate-buffered solution with pH
6.7 is available as Nutrineal (Baxter Healthcare Corpo-
ration). The solution has an osmolality of 365 mOsm/kg
H2O and contains 87 mmol/L amino acids, 61% of which
are essential amino acids. An in vitro study with poly-
morphonuclear leukocytes showed better viability and
phagocytosis when compared to glucose-based solutions,
but no difference was found in bactericidal capacity [82].
An ex vivo study by the same group showed that peri-
toneal macrophages isolated from amino acid effluent
also had better phagocytosis than those from the glucose-
based solution and a lower secretion of IL-1b and IL-8
[83]. Peritoneal transport studies showed that the 1.1%
amino acid solution increased peritoneal blood flow by
55% [84]. The effect on MTACs of low molecular weight
solutes was significant, but small. Furthermore, peri-
toneal albumin loss was similar to that during a glucose-
based exchange.
Clinical use of the 1.1% amino acid dialysis solution
Malnutrition in dialysis patients is multifactorial. It re-
sults from a combination of poor protein and energy
intake, the presence of intercurrent illness and chronic
inflammation, metabolic and endocrine disturbances,
protein and amino acid loss through PD itself, and general
physical inactivity.
Albumin losses constitute 63% of total protein lost in
the dialysate. It has been shown that amino acid–based
PD solutions can replace amino acids lost during PD and
correct protein malnutrition. With a single exchange co-
inciding with the major meal of the day (lunch time or tea
time), the 1.1% amino acid solution can deliver 25% of
the target daily protein intake in the average adult [85].
With an absorption rate of 70% to 80% over 4 to 6 hours,
1 2 L exchange of the 1.1% amino acid solution provides
approximately 18 g of amino acids to an average, stable,
60 kg patient (i.e., 0.3 g/kg body weight/day), which repre-
sents 25% of the target intake of 1.2 g/kg body weight/day.
Furthermore, dietary protein supplements contain on av-
erage 15 mg phosphorus per gram of protein, adding an
additional 300 mg of phosphorus load for every 0.3 g/kg
protein supplementation. The new 1.1% amino acid solu-
tion achieves amino acid supplementation without phos-
phorus loading.
One exchange of the 1.1% amino acid solution per day
has been shown to improve nitrogen balance and bio-
chemical markers of nutrition in malnourished CAPD
patients [86]. Studies with 15N-glycine [86], 2H3 leucine,
and 13C leucine [87] demonstrated that the 1.1% amino
acid solution could be used for protein synthesis without
an effect on protein breakdown. Mild metabolic acidosis
has been reported, especially when used for 2 exchanges
per day instead of 1. A 3-month prospective study of the
1.1% amino acid solution in CAPD patients with a wide
variation in nutritional status reported increases in serum
albumin and transferrin, a mild increase in plasma urea,
and no effect on bicarbonate with 1 exchange per day [88].
Side effects include dose-dependent episodes of nausea,
vomiting, and unspecific gastrointestinal symptoms. To
prevent these symptoms, patients should be monitored,
and oral alkalinizing agents, such as sodium bicarbonate,
used as needed.
In addition to its use in malnutrition, this 1.1% amino
acid solution also can be used in a dialysis prescription




A glucose-based dialysis solution buffered with a com-
bination of 25 mmol/L bicarbonate and 15 mmol/L lac-
tate is available in many countries (Physioneal, Baxter
Healthcare Corporation). The osmolality of this solu-
tion is similar to that of standard glucose-based solu-
tions, but the pH is 7.4. The bicarbonate/lactate solution
is prepared in a double-chamber bag; 1 chamber con-
tains glucose, calcium chloride, and magnesium chloride,
and the other chamber contains sodium chloride, sodium
bicarbonate, and sodium lactate. As a result of this two-
chamber configuration, the pH of the glucose-containing
compartment is markedly lower than 5.2, which results
in a lower content of GDPs [89]. In vitro studies with
the murine fibroblast cell line L 929 showed less inhi-
bition of growth with bicarbonate/lactate compared to a
standard lactate-based solution containing 3.86% glucose
[89]. The rationale for combining bicarbonate with lac-
tate was the high pCO2 associated with 35 to 40 mmol/L
bicarbonate, and in vitro studies showing that high con-
centrations of bicarbonate were cytotoxic, presumably
due to a paradoxic intracellular acidification caused by
influx of carbon dioxide [90, 91]. However, an in vitro
study comparing the effects of a bicarbonate/lactate so-
lution to those of a bicarbonate-only buffered dialysate
showed no significant differences between the 2 with re-
gard to their effects on cultured mesothelial cells and
peripheral polymorphonuclear leucocytes [92]. An ex
vivo study on peritoneal macrophages showed that their
secretion of TNFa was higher when they were iso-
lated from bicarbonate/lactate-buffered solutions than
when isolated from bicarbonate- or lactate-only buffered
effluent [93].
A 10-week study using the long-term peritoneal ex-
posure model in the rat showed that bicarbonate/lactate
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preserved mesothelial integrity better than a standard
lactate solution, and improved the ex vivo bacterial clear-
ing capacity [94]. However, no effect was found in the
density of mesothelial cells on the liver surface and the
thickness of the submesothelial compact zone. Exposure
for 12 to 20 weeks in the same model resulted in a decrease
in the number of peritoneal vessels by about 50%, and
a reduction in the amount of omental fibrosis [abstract;
Zweers MM, Perit Dial Int 21(Suppl 1):S21, 2001].
Clinical use of bicarbonate/lactate-buffered solution
The first clinical study was aimed at comparing the
safety and efficacy of a bicarbonate- and a bicarbonate/
lactate-buffered dialysis solution [95, 96]. No differences
were found in plasma bicarbonate or lactate concentra-
tions between the 2 solutions. A randomized blinded
clinical study demonstrated that the bicarbonate/lactate
solution could alleviate infusion pain more effectively
than pure bicarbonate- or lactate-based fluids [97]. A ran-
domized prospective, controlled, 12-month study com-
paring bicarbonate/lactate and standard lactate solutions
showed that both solutions were equivalent with regard to
plasma bicarbonate level and peritoneal solute transport
[98]. However, greater ultrafiltration volume of about
150 mL/day was reported for the bicarbonate/lactate so-
lution, as well as a lower incidence of peritonitis. These
preliminary data on peritonitis were confirmed by the
European PD Solutions Registry, in which a significant
reduction in peritonitis rate was observed in patients
treated with the bicarbonate/lactate solution compared
to those treated with standard lactate solutions [abstract;
Van Bree M, J Am Soc Nephrol 13:S43A, 2002]. A non-
randomized 8-week study also reported good correction
of acid-base status, but no effect on ultrafiltration [99].
This may have been due to the short duration of treat-
ment, or to the use of icodextrin by all patients, which
may have masked any effect of the bicarbonate/lactate
solution on ultrafiltration.
Interesting results were obtained when effluent con-
centrations of markers that may reflect the status of the
peritoneal membrane were analyzed. The concentration
of dialysate cancer antigen 125 (CA 125) increased sig-
nificantly and the concentration of hyaluronan decreased
[100]. These changes were not present in the control
group. Dialysate CA 125 is a marker of mesothelial cell
mass or turnover [101], while dialysate hyaluronan has
been considered to reflect peritoneal inflammation [102].
Similar changes in CA 125 and hyaluronan have been
reported for a lactate-buffered solution with a very low
content of GDPs and a pH of 6.8 [103]. A recent analysis
of bicarbonate/lactate effluent also found reduced levels
of IL-6 and VEGF [104].
Some of the clinical observations fit very well with
the experimental results. For instance, the lower inci-
dence of peritonitis might be related to better function-
ing macrophages and neutrophils, the higher effluent CA
125 levels might reflect the lager mesothelial cell mass re-
ported in rats, and the lower number of peritoneal vessels
in rats may be in accordance with the somewhat increased
ultrafiltration and lower effluent VEGF concentrations
in patients. Although no long-term clinical studies with
the bicarbonate/lactate solution are yet available, the re-
sults of the experimental studies and the clinical evidence
to date suggest that this solution is less harmful to the
peritoneal membrane than conventional glucose/lactate-
based solutions.
A SOLUTIONS PORTFOLIO APPROACH IN
PERITONEAL DIALYSIS
No currently available PD solution meets all require-
ments to be considered an ideal solution: effective ultra-
filtration; no long-term effects on membrane function;
correction of metabolic and nutritional abnormalities.
However, a multiple solution regimen that would take
advantage of the features of 1 or more of the new solu-
tions may come closer to achieving these goals, and would
provide a much more balanced dialysis prescription than
standard glucose-based solutions alone. The advantages
and disadvantages of the individual solutions are summa-
rized in Table 3.
In addition to studies that have evaluated these solu-
tions individually, studies also have investigated the long-
term effects of a combination of 2 [99] or all 3 solutions. A
three-solution prescription would provide a marked re-
duction in the exposure of the peritoneum to glucose and
GDPs, while also providing enhanced ultrafiltration and
a more balanced absorption of nutrients. Preliminary ev-
idence suggests that this combination provides equal or
superior efficacy to a standard glucose regimen, with po-
tential added benefits to membrane function. An open,
randomized, prospective, crossover, multicenter trial in
78 new CAPD patients compared a standard glucose-
based, lactate-buffered PD regimen (SPD) with a reg-
imen consisting of 1 daily exchange (long dwell) with
icodextrin, 2 with bicarbonate/lactate, and 1 with 1.1%
amino acid solution (ENP). An interim analysis after
6 months (56 patients) found that patients on SPD had
an increase in body weight (70.3 ± 14.8 to 72.1 ± 14.4 kg,
P < 0.05), whereas in patients on the ENP regimen, body
weight tended to decrease (75.4 ± 14.8 to 74.6 ± 12.3 kg,
P = NS). Average ultrafiltration rate was similar in the
2 groups. Residual creatinine clearance fell in SPD pa-
tients (7.3 ± 3.6 to 4.7 ± 3.8 mL/min, P < 0.02), but did
not change significantly in ENP patients (5.4 ± 4.0 to
4.0 ± 2.7 mL/min) [abstract; le Poole C, Perit Dial Int.
23(Suppl 1):S52, 2003). Patients on SPD had an approxi-
mate 50% reduction in peritoneal leukocyte count com-
pared to the ENP group (P <0.05), indicating a hampered
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Table 3. Advantages and disadvantages of the new solutions portfolio approach to prevent long-term peritoneal membrane alterations
Advantages Disadvantages
Icodextrin Ultrafiltration ↑ Low pH, lactate-buffered
Glucose exposure ↓ Once daily for the long dwell
GDP exposure ↓
1.1% amino acid solution Amino acid supply ↑ Lactate-buffered
Glucose exposure ↓↓ Once daily UF similar to 1.36% glucose
GDP exposure ↓↓
Bicarbonate/lactate-buffered solution Normal pH Glucose as osmotic agent




GDP, glucose degradation product; UF, ultrafiltration.
leukocyte migration to the peritoneal cavity in response
to high glucose load [abstract; Welten AGA, J Am Soc
Nephrol 13:202A, 2002].
Nevertheless, despite the fact that this new combi-
nation of solutions may enhance technique and patient
survival, more studies are needed to determine how to
optimally use the various combinations of osmotic agents
and buffers, and how to tailor the dialysis prescription to
meet individual patient needs. It is possible that an ap-
proach using multiple solutions may have additive bene-
ficial effects combined with a reduction in toxicity of each
separate component.
Reprint requests to R.T. Krediet, M.D., Ph.D., Academic Medical




1. HEIMBU¨RGER O, WANIEWSKI J, WERYNSKI A, et al: Peritoneal trans-
port in CAPD patients with permanent loss of ultrafiltration ca-
pacity. Kidney Int 38:495–506, 1990
2. DOBBIE JW: Pathogenesis of peritoneal fibrosing syndromes (scle-
rosing peritonitis) in peritoneal dialysis. Perit Dial Int 12:14–27,
1992
3. WILLIAMS JD, CRAIG KJ, TOPLEY N, et al: Morphologic changes in
the peritoneal membrane of patients with renal disease. J Am Soc
Nephrol 13:470–479, 2002
4. MATEIJSEN MAM, VAN DER WAL AC, HENDRIKS PMEM, et al: Vas-
cular and interstitial changes in the peritoneum of CAPD patients
with peritoneal sclerosis. Perit Dial Int 19:517–525, 1999
5. HONDA K, NITTA K, HORITA H, et al: Morphological changes in the
peritoneal vasculature of patients on CAPD with ultrafiltration
failure. Nephron 72:171–176, 1996
6. GOTLOIB L, BAR-SELLA P, SHOSTAK A: Reduplicated basal lamina
of small venules and mesothelium of human parietal peritoneum.
Perit Dial Bull 5: 212–215, 1985
7. DIPAOLO N, SACCHI G: Peritoneal vascular changes in continuous
ambulatory peritoneal dialysis (CAPD): An in vivo model for the
study of diabetic microangioopathy. Perit Dial Int 9:41–45, 1989
8. DOBBIE JW, ANDERSON JD, HIND C: Long-term effects of peritoneal
dialysis on peritoneal morphology. Perit Dial Int 14(Suppl 3):S16–
S20, 1994
9. YAMADA K, MIYAHARA Y, HAMAGUCHI K, et al: Immunohistochem-
ical study of human advanced glycosylation end-products (AGE)
in chronic renal failure. Clin Nephrol 42:354–361, 1994
10. NAKAYAMA M, KAWAGUCHI Y, YAMADA K, et al: Immunohisto-
chemical detection of advanced glycosylation end-products in the
peritoneum and its possible pathophysiological role in CAPD. Kid-
ney Int 51:182–186, 1997
11. DAVIES SJ, BRYAN J, PHILIPS L, RUSSEL GI: Longitudinal changes in
peritoneal kinetics: the effects of peritoneal dialysis and peritonitis.
Nephrol Dial Transplant 11:498–506, 1996
12. ZWEERS MM, SPLINT LJ, KREDIET RT, STRUIJK DG: Ultrastructure
of basement membranes of peritoneal capillaries in a chronic peri-
toneal infusion model in the rat. Nephrol Dial Transplant 16:651–
654, 2001
13. HENDRIKS PMEM, HO-DAC-PANNEKEET MM, VAN GULIK TM, et al:
Peritoneal sclerosis in chronic peritoneal dialysis patients: Anal-
ysis of clinical presentation, risks factor and peritoneal transport
characteristics. Perit Dial Int 17:136–143, 1997
14. DAVIES SJ, PHILLIPS L, NAISH PF, RUSSEL GI: Peritoneal glucose
exposure and changes in membrane solute transport with time on
peritoneal dialysis. J Am Soc Nephrol 12:1046–1051, 2001
15. TOPLEY N, COLES GA, WILLIAMS JD: Biocompatibility studies on
peritoneal cells. Perit Dial Int 14(Suppl 3):S21–S28, 1994
16. PEDERSEN FB, RYTTOV N, DELEURAN P, et al: Acetate versus lactate
in peritoneal dialysis solutions. Nephron 39:55–58, 1985
17. MAHIOUT A, BRUNKHORST R: Pyruvate anions neutralize peritoneal
dialysate toxicity. Nephrol Dial Transplant 10:391–394, 1995
18. SHOSTAK A, GOTLOIB L, KUSHNIER R, WAJSBROT V: Protective ef-
fect of pyruvate upon cultured mesothelial cells exposed to 2 mM
hydrogen peroxide. Nephron 4:362–366, 2000
19. BEYER-MEARS A, DIECKE FP, MISTRY K, et al: Effect of pyruvate
on lens myo-inositol transport and polyol formation in diabetic
cataract. Pharmacology 55:78–86, 1997
20. WONG TYH, PHILIPS AO, WITOWSKI J, TOPLEY N: Glucose-mediated
induction of TGF-b and MCP-1 in mesothelial cells in vitro is
osmolality and polyol pathway dependent. Kidney Int, in press
21. BREBOROWICZ A, RODELA H, OREOPOULOS DG: Toxicity of osmotic
solutes on human mesothelial cells in vitro. Kidney Int 41:1280–
1285, 1992
22. GOTLOIB L, WAISBRUT V, SHOSTAK A, KUSHNIER R: Acute and long-
term changes observed in imprints of mouse mesothelium exposed
to glucose enriched, lactate buffered dialysis solution. Nephron
70:466–477, 1995
23. KUMANO K, SCHILLER B, HJELLE JT, et al: Effect of osmotic so-
lutes on fibronectin mRNA expression in rat peritoneal mesothe-
lial cells. Blood Purif 14:165–169, 1996
24. ZWEERS MM, DE WAART DR, SMIT W, et al: Growth factors VEGF
and TGF-b1 in peritoneal dialysis. J Lab Clin Med 134:124–132,
1999
25. ZWEERS MM, STRUIJK DG, SMIT W, KREDIET RT: Vascular endothe-
lial growth factor in peritoneal dialysis. A longitudinal follow-up.
J Lab Clin Med 137:125–132, 2001
26. HONDA K, NITTA K, HORITA S, et al: Accumulation of advanced
glycation end-products in the peritoneal vasculature of continuous
ambulatory peritoneal dialysis patients with ultrafiltration failure.
Nephrol Dial Transplant 14:1541–1549, 1999
27. FRIEDLANDER MA, WU Y-C, SCHALAK JA, et al: Influence of dialysis
modality on plasma and tissue concentrations of pentosidine in
patients with end-stage renal disease. Am J Kidney Dis 25:445–
451, 1995
28. DEGENHARDT TP, GRASS L, REDDY S, et al: The serum
concentration of the advanced glycation end-products in
S-122 Vardhan et al: A solutions portfolio approach in PD
N-(carboxymethyl)lysine is increased in uremia. Kidney Int
52:1064–1067, 1997
29. MIYATA T, VAN YPERSELE-DE STRIHOU C, KUROKAWA G, BAYNES
JN: Alterations in non-enzymatic biochemistry in uremia: Origin
and significance of “carbonyl stress” in long-term uremic compli-
cations. Kidney Int 55:389–399, 1999
30. MIYATA T, KEDA Y, YAMADA Y, et al: Accumulation of carbonyl
accelerates the formation of pentosidine, in advanced glycation
end-products: Carbonyl stress in uremia. J Am Soc Nephrol 9:2349–
2356, 1998
31. WEISS MF, ERHARD P, KADER-ATTIA FA, et al: Mechanisms for
the formation of glyoxidation products in end-stage renal disease.
Kidney Int 57:2571–2585, 2000
32. MIYATA T, ISHIKAWA S, ASAKI K, et al: 2-Isopropylidenehydroazo-
4-oxo-thiazolin-5-ylacetanilide-(OPB-9195) treatment inhibits the
development of intimal thickening after balloon injury of rat
carotics artery: Role of glyoxidation and lipoxidation reactions in
vascular tissue damage. FEBS Letters 445:202–206, 1999
33. FRIEDLANDER MA, WITKO-SARSAT V, NGAYEN AT, et al: The ad-
vanced glycation end-product pentosidine and monocyte activa-
tion in uremia. Clin Nephrol 45:379–382, 1996
34. AMORE A, CIRINA P, MITOLA S, et al: Non-enzymatically glycated
albumin (Amadori adducts) enhances nitric oxyde synthase activ-
ity and gene expression in endothelial cells. Kidney Int 51:27–35,
1997
35. HO-DAC-PANNEKEET MM, WEISS MF, DE WAART DR, et al: Analysis
of non-enzymatic glycosylation in vivo: Impact of different dialysis
solutions. Perit Dial Int 19(Suppl 2):S68–S74, 1999
36. WIESLANDER AP, NORDIA MK, KJELLSTRAND PTT, BOBERG UC:
Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929.
Kidney Int 40:77–79, 1991
37. LINDEN T, COHEN A, DEPPISCH R, et al: 3,4-Dideoxyglucosone-3-
ene (3,4–DGE): A cytoxic glucose degradation product in fluids
for peritoneal dialysis. Kidney Int 62:697–703, 2002
38. WITOWSKI J, KORYBALSKA K, WISNIEWSKA J, et al: Effect of glucose
degradation products on human peritoneal mesothelial cell func-
tion. J Am Soc Nephrol 11:729–739, 2000
39. INAGI R, MIYATA T, YAMAMOTO T, et al: Glucose degradation prod-
uct methylglyoxal enhances the production of vascular endothe-
lial growth factor in peritoneal cells: A role in the functional and
morphological alterations of peritoneal membrane in peritoneal
dialysis. FEBS Letters 463:260–264, 1999
40. MIYATA T, HORIE K, UEDA Y, et al: Advanced glycation and lipidox-
idation of the peritoneal membrane: Respective roles of serum and
peritoneal fluid reactive carbonyl compounds. Kidney Int 58:425–
435, 2000
41. ZEIER M, SCHWENGER V, DEPPISCH R, et al: Glucose degradation
products in PD fluids: Do they disappear from the peritoneal cavity
and enter the systemic circulation? Kidney Int 63:248–305, 2003
42. HO T, YORIOKA N, YAMAMOTO M, et al: Effect of glucose on inter-
cellular junction of cultured human peritoneal mesothelial cells. J
Am Soc Nephrol 11:1969–1979, 2000
43. SITTER T, HASLINGER B, MANDL S, et al: High glucose increases
prostaglandin E2 synthesis in human peritoneal mesothelial cells:
Role of hyperosmolarity. J Am Soc Nephrol 9:2005–2012, 1998
44. SITTER T, MANDL-WEBER S, WORNLE M, et al: D-Glucose increases
the synthesis of tissue-type plaminogen activator (t-PA) in human
peritoneal mesothelial cells. Thromb Haemost 82:1171–1176, 1999
45. KANG DH, HONG YS, LIM HJ, et al: High glucose solution and spent
dialysate stimulate the synthesis of transforming growth factor b1
of human peritoneal mesothelial cells: Effect of cytokine costimu-
lation. Perit Dial Int 19:221–230, 1999
46. HU H, YU MR, LEE HB: High glucose-induced PKL activa-
tion medicates TGF-b1 and fibronectin synthesis by peritoneal
mesothelial cells. Kidney Int 59:463–470, 2001
47. ROUGIER J-P, MOULLIER P, PIEDAGNEL R, et al: Hyperosmolality
suppresses, but TGF-b1 increases MMP 9 in human peritoneal
mesothelial cells. Kidney Int 51:337–347, 1997
48. LIEBEREK T, TOPLEY N, JO¨RRES A, et al: Peritoneal dialysis fluid
inhibition of phagocytic fucntion: Effects of osmolality and glucose
concentration. J Am Soc Nephrol 3:1508–1515, 1993
49. GOTLOIB L, WAJSHBROT V, SHOSTAK A, KUSHNIER R: Effects of hy-
perosmolarity upon the mesothelial monolayer exposed in vivo
and in situ to a mannitol-enriched dialysis solution. Nephron
81:305–309, 1999
50. HO-DAC-PANNEKEET MM, SCHOUTEN N, LANGEDIJK MJ, et al:
Peritoneal transport characteristics with glucose polymer based
dialysate. Kidney Int 50:979–986, 1996
51. LIBEREK T, TOPLEY N, MISTRY CD, et al: Cell function and viability
in glucose polymer peritoneal dialysis fluid. Perit Dial Int 13:104–
111, 1993
52. JO¨RRES A, GAHL GM, TOPLEY N, et al: In vitro biocompatibility of
alternative CAPD fluids: Comparison of bicarbonate buffered and
glucose polymer based solutions. Nephrol Dial Transplant 9:785–
790, 1994
53. THOMAS S, SCHENK U, and FISCHER F, et al: In vitro effects of glu-
cose polymer-containing peritoneal dialysis fluids on phagocytic
activity. Am J Kidney Dis 29:246–253, 1997
54. DE FIJTER CWH, VERBRUGH HA, OE LP, et al: Biocompatibility of a
glucose polymer-containing peritoneal dialysis fluid. Am J Kidney
Dis 4:411–418, 1993
55. BAJO MA, SELGAS R, CASTRO MA, et al: Icodextrin effluent leads to
a greater proliferation than glucose effluent of human mesothelial
cells studies ex vivo. Perit Dial Int 20:742–747, 2000
56. MISTRY CD, GOKAL R, PEERS E: A randomized multicenter clinical
trial comparing isosmolar icodextrin with hyperosmolar glucose
solution in CAPD. MIDAS Study Group. Multicenter Investiga-
tion of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int
46:496–503, 1994
57. WOLFSON M, PIRAINO B, HAMBURGER RJ, MORTON AR: A random-
ized controlled trial to evaluate the efficacy and safety of icodextrin
in peritoneal dialysis. Am J Kidney Dis 40:1055–1065, 2002
58. POSTHUMA N, TER WEE PM, VERBRUGH HA, et al: Icodextrin in-
stead of glucose during the daytime dwell in CCPD increases ul-
trafiltration and 24-h dialysate creatinine clearance. Nephrol Dial
Transplant 12:550–553, 1997
59. PLUM J, GENTILE S, VERGER C, et al: Efficacy and safety of a
7.5% icodextrin peritoneal dialysis solution in patients treated
with automated peritoneal dialysis. Am J Kidney Dis. 39:862–871,
2002
60. ARAUJO MRT, RAMAO JE, SABBAGA E, et al: The relationship be-
tween ultrafiltrate volume with icodextrin and peritoneal transport
pattern according to the peritoneal equilibration test. Perit Dial Int
22:229–233, 2002
61. IMHOLZ ACT, BROWN CB, KOOMEN GCM, et al: The effect of glu-
cose polymers on water removal and protein clearances during
CAPD. Adv Perit Dial 9:25–30, 1993
62. PEERS EM, SCRIMGEOUR AC, HAYCOX AR: Cost-containment in
CAPD patients with ultrafiltration failure. Clin Drug Invest 10:53–
58, 1995
63. WILKIE ME, PLANT MJ, EDWARDS L, BROWN CB: Icodextrin 7.5%
dialysate solution (glucose polymer) in patients with ultrafiltra-
tion failure: Extension of CAPD technique survival. Perit Dial Int
17:84–97, 1997
64. JOHNSON DW, ARNDT M, O’SHEA A, et al: Icodextrin as salvage ther-
apy in peritoneal dialysis patients with refractory fluid overload.
BMC Nephrol 2:2, 2001
65. KREDIET RT, ZUYDERHOUDT FM, BOESCHOTEN EW, ARISZ L: Al-
terations in the peritoneal transport of water and solutes during
peritonitis in continuous ambulatory peritoneal dialysis patients.
Eur J Clin Invest 17:43–52, 1987
66. DOUMA CE, DE WAART DR, STRUIJK DG, KREDIET RT: Are
phospholipase A2 and nitric oxide involved in the alterations in
peritoneal transport during CAPD peritonitis? J Lab Clin Med
132:329–340, 1998
67. PANNEKEET MM, IMHOLZ AL, STRUIJK DG, et al: The standard peri-
toneal permeability analysis: A tool for the assessment of peri-
toneal permeability characteristics in CAPD patients. Kidney Int
48:866–875, 1995
68. CARLSSON O, RIPPE B: Peritoneal lymphatic absorption and so-
lute exchange during zymosan-induced peritonitis in the rat. Am
J Physiol 277:H1107–H1112, 1999
69. GOKAL R, MISTRY CD, PEERS EM: Peritonitis occurrence in a
multicentre study of icodextrin and glucose in CAPD. MIDAS
Study Group. Multicentre Investigation of Icodextrin in Ambula-
tory Dialysis. Perit Dial Int 15:226–230, 1995
Vardhan et al: A solutions portfolio approach in PD S-123
70. POSTHUMA N, TER WEE PM, DONKER, et al: Icodextrin use in CCPD
patients during peritonitis: Ultrafiltration and serum disaccharide
concentrations. Nephrol Dial Transplant 13:2341–2344, 1998
71. POSTHUMA N, TER WEE PM, DONKER, et al: Assessment of the effec-
tiveness, safety, and biocompatibility of icodextrin in automated
peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA)
Group. Perit Dial Int 20(Suppl 2):S106–S113, 2000
72. MISTRY CD, O’DONOGHUE DJ, NELSON S, et al: Kinetic and clinical
studies of b2-microglobulin in contiunous ambulatory peritoneal
dialysis: Influence of renal and enhanced peritoneal clearances us-
ing glucose polymer. Nephrol Dial Transplant 5:513–519, 1990
73. KREDIET RT, BROWN CB, IMHOLZ ALT, KOOMEN GCM: Protein
clearance and icodextrin. Perit Dial Int 14(Suppl 2):S39–S44, 1994
74. DELARUE J, MAINGOURD C, LAMISSE F, et al: Glucose oxidation after
a peritoneal and an oral glucose load in dialyzed patients. Kidney
Int 45:1147–1152, 1994
75. WOODROW G, OLDROYD B, STABLES G, et al: Effects of icodextrin in
automated peritoneal dialysis on blood pressure and biolelectrical
impedance analysis. Nephrol Dial Transplant 15:862–866, 2000
76. KONINGS CJ, KOOMAN JP, SCHONCK M, et al: Fluid status in CAPD
patients is related to peritoneal transport and residual renal func-
tion: Evidence from a longitudinal study. Nephrol Dial Transplant
18:797–803, 2003
77. KONINGS CJ, KOOMAN JP, SCHONCK M, et al: Effect of icodextrin on
volume status, blood pressure and echocardiographic parameters:
A randomized study. Kidney Int 63:1556–1563, 2003
78. BROWN EA, DAVIES SJ, HEIMBURGER O, et al: Adequacy targets
can be met in anuric patients by automated peritoneal dialysis:
Baseline data from EAPOS. Perit Dial Int 21(Suppl 3):S133–S137,
2001
79. OYIBO SO, PRITCHARD GM, MCLAY L, et al: Blood glucose overes-
timation in diabetic patients on continuous ambulatory peritoneal
dialysis for end-stage renal disease. Diabet Med 19:693–696, 2002
80. WENS R, TAMINNE M, DEVRIENDT J, et al: A previously undescribed
side effect of icodextrin: Overestimation of glycemia by glucose
analyzer. Perit Dial Int 18:603–609, 1998
81. SCHOENICKE G, GRABENSEE B, PLUM J: Dialysis with icodextrin
interferes with measurement of serum alpha-amylase activity.
Nephrol Dial Transplant 17:1988–1992, 2002
82. BRULEZ HFH, HEEZIUS ECJM, DE FIJTER CWJ, et al: In vitro com-
patibility of a 1.1% amino acid containing peritoneal dialysis fluid
with phagocyte function. Adv Perit Dial 10:241–244, 1994
83. BRULEZ HFH, DEKKER HA TH, OE PL, et al: Biocompatibility of
a 1.1% aminoacid containing peritoneal dialysis (PD) fluid com-
pared to a 2.27% glucose-based PD-fluid. Nephron 74:26–32, 1996
84. DOUMA CE, DE WAART DR, STRUIJK DG, KREDIET RT: Effect of
amino acid based dialysate on peritoneal blood flow and perme-
ability in stable CAPD patients: A potential role for nitric oxide?
Clin Nephrol 45:295–302, 1996
85. JONES MR, GEHR TW, BURKART JM, et al: Replacement of amino
acid and protein losses with 1.1% amino acid peritoneal dialysis
solution. Perit Dial Int 18:210–216, 1998
86. KOPPLE JD, BERNARD D, MESSANA J, et al: Treatment of malnour-
ished CAPD patients with an amino acid based dialysate. Kidney
Int 47:1148–1157, 1995
87. DELARUE J, MAINGOURD C, OBJOIS M, et al: Effects of an amino
acid dialysate on leucine metobolism in continuous ambulatory
peritoneal dialysis patients. Kidney Int 56:1934–1943, 1999
88. FALLER B, APARICIO M, FAICT D, et al: Clinical evaluation of an op-
timized 1.1% amino acid solution for peritoneal dialysis. Nephrol
Dial Transplant 10:1432–1437, 1995
89. COOKER CA, LUNEBURG P, FAICT D, et al: Reduced glucose degra-
dation products in bicarbonate/lactate-buffered peritoneal dialysis
solutions produced in two-chambered bags. Perit Dial Int 17:373–
378, 1997
90. SCHAMBYE HT, PEDERSON FB, WANG P: Bicarbonate is not the ulti-
mate answer to the biocompatibility problems of CAPD solutions:
A cytotoxicity test of CAPD solutions and effluents. Adv Perit Dial
8:42–46, 1992
91. SCHAMBYE HT: Effects of different buffers on the biocompatibility
of CAPD solutions. Perit Dial Int 16(Suppl 1):S130–S136, 1996
92. TOPLEY N, KAUR D, PETERSEN MM, et al: In vitro effects of bicar-
bonate and bicarbonate/lactate-buffered peritoneal dialysis solu-
tions on mesothelial and neutrophil function. J Am Soc Nephrol
7:218–224, 1996
93. MACKENZIE RK, HOLMER CJ, MOSELEY A, et al: Bicarbonate/
lactate- and bicarbonate-buffered peritoneal dialysis fluids im-
prove ex vivo peritoneal macrophase TNFa secretion. J Am Soc
Nephrol 9:1499–1506, 1998
94. HEKKING LHP, ZAREIE M, DRIESPRONG BAJ, et al: Better preserva-
tion of peritoneal morphologic features and defence in rats after
long-term exposure to a bicarbonate/lactate-buffered solution. J
Am Soc Nephrol 12:1775–2786, 2001
95. COLES GA, GOKAL R, OGG C, et al: A randomized controlled trial
of a bicarbonate- and a bicarbonate/lactate-containing dialysis so-
lution in CAPD. Perit Dial Int 17:48–51, 1997
96. COLES GA, O’DONOGHUE, DJ, PRITCHARD N, et al: A controlled trial
of two bicarbonate-containing dialysis fluids for CAPD—Final re-
port. Nephrol Dial Transplant 13:3165–3171, 1998
97. MACTIER RA, SPROSEN TS, GOKAL R, et al: Bicarbonate and bi-
carbonate/lactate PD solutions for the treatment of infusion pain.
Kidney Int 53:1061–1067, 1998
98. TRANAEUS A, for the Bicarbonate/lactate Study Group: A
long-term study of a bicarbonate/lactate-based peritoneal dial-
ysis solution—Clinical benefits. Perit Dial Int 20:516–523,
2000
99. OTTE K, GONZALEZ T, BAJO M-A, et al: Clinical experience with
a new bicarbonate (25 mmol/L)/lactate (10 mmol/L) peritoneal
dialysis solution. Perit Dial Int 23:138–145, 2003
100. JONES S, HOLMES CJ, KREDIET RT, et al: Bicarbonate/lactate-
based peritoneal dialysis solution increases cancer antigen 125
and decreases hyalyronic acid levels. Kidney Int 59:1529–1538,
2001
101. KREDIET RT: Dialysate cancer antigen 125 concentration as a
marker of peritoneal membrane status in patients treated with
chronic peritoneal dialysis. Perit Dial Int 21: 560–567, 2001
102. HO-DAC-PANNEKEET MM, KREDIET RT: Inflammatory changes in
vivo during CAPD: What can the effluent tell us? Kidney Int
50(Suppl 56):S12–S16, 1996
103. RIPPE B, SIMONSEN O, HEIMBU¨RGER O, et al: Long-term clinical
effects of a peritoneal dialysis fluid with less glucose degradation
products. Kidney Int 59:348–357, 2001
104. DEVUYST O, TOPLEY N, WILLIAMS JD: Morphological and functional
changes in the dialysed peritoneal cavity: Impact of more bio-
compatible solutions. Nephrol Dial Transplant 17(Suppl 3):12–15,
2002
